Health & Wellness Akero Therapeutics nearly doubles stock price on positive clinical studies MASH is a more severe form of metabolic dysfunction-associated steatotic liver disease formerly known as non-alcoholic fatty liver disease Joseph MortonJanuary 27, 2025
Bitcoin Bit Digital inks new deal to bring GPU firepower, and bumps $15M in revenue Bit Digital has ordered 58 Nvidia B200 servers for approximately USD$21 million Joseph MortonJanuary 24, 2025
Technology Viasat shares lift off 40% on NASA services contract The Viasat RTE network integrates advancements in artificial intelligence, machine learning, and cloud-based optimization Joseph MortonJanuary 21, 2025
AI and Autonomy IonQ inks research deal with United States Air Force for quantum computing IonQ will develop a network with high-performing access points for quantum computers and networked devices Joseph MortonJanuary 15, 2025
Gold Small-cap mining companies doing the work: A Mugglehead roundup These companies are generally considered to have high growth potential but may also carry higher risk Joseph MortonJanuary 10, 2025
Medical and Pharmaceutical Sana Biotechnology could offer relief to diabetes type 1 sufferers in the future The study showed that Sana's hypoimmune (HIP) modified pancreatic islet cells could successfully evade the patient's immune system Joseph MortonJanuary 9, 2025
Health & Wellness Orchestra BioMed shares get shot in the arm on solid clinical trial data This study targets a significant patient population with hypertension, and holds promise for substantial market impact if successful Joseph MortonJanuary 2, 2025
Medical and Pharmaceutical Sagimet Biosciences up 30% on strong clinical stage data Denifanstat received FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis Joseph MortonDecember 16, 2024
Driving Titan International enjoys over 50% stock bump on institutional investor attention Several major investors have also recently adjusted their holdings in Titan International Joseph MortonDecember 9, 2024
Medical and Pharmaceutical Janux Therapeutics soars on clinical trial data for prostate cancer treatment candidate For 63 per cent of patients, the cancer was either reduced or kept from worsening Joseph MortonDecember 3, 2024